Pharmacokinetics and tolerability of 40-0-[2-Hydroxyethyl]rapamycin in de novo liver transplant recipients

Transplantation

Volumn 71, Issue 1, 2001, Pages 160-163

  Levy, Gary A ^a   Grant, David ^b   Paradis, Khazal ^c   Campestrini, Joelle ^d   Smith, Tom ^e   Kovarik, John M ^e  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Imutran Ltd   (United Kingdom)

^d NOVARTIS PHARMA K K   (Japan)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; RAPAMYCIN;

ADULT; ALLOGRAFT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT;

EID: 0035862975     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200101150-00028     Document Type: Article

References (9)

1. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
2. Multiple-dose pharmacokinetics of the immunosuppressant SDZ RAD in stable renal transplant patients
3. Rapamune (sirolimus, rapamycin): An overview and mechanism of action
4. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation
5. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model
6. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine
7. Multicenter, randomized, double-blind, dose-finding study evaluating the efficacy and safety of RAD001 (RAD) in de novo renal transplant recipients
8. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
9. Steady-state pharmacokinetics and tolerability of RAD and its influence on cyclosporine in stable renal transplant patients